Amicus Therapeutics (FOLD) Stock Price, Quote & News

Company Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with lat...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 662 2000

Fax: 609 662 2001

Website: amicusrx.com

Address:

47 Hulfish Street, Princeton, United States

Capitulation_0 Mar. 13 at 7:55 PM

$ARDX Just find this interesting...Not suggesting that ARDX will play out in similar fashion but really speaks to Rabbs ability... Rabb was appointed chair of $FOLD on 3/2024, stock was trading $11-$13. In Jan 2025, the stock was trading around $5 due to missing guidance and high expenses. After this, he prioritized the global launch and revenue growth of Galafold (for Fabry disease) and Pombiliti + Opfolda (for Pompe disease). These products achieved significant combined product revenues (approx. $599M in late 2025), making the company an attractive acquisition target. One of the fastest turnaround story that ended with a Buyout at $14.5 -- all cash.

0 · Reply

Night_Owl_Biotech Mar. 11 at 2:14 AM

The attachment compares $SLNO 7-year analyst consensus revenue estimates to the same 7-year revenue forecasts prepared by the management/BOD of 15 comm'l-stage peers that exited via M&A. The table is sorted lowest cumulative 7-year revenue forecast to highest (with M&A exit valuations noted). Analysts forecast SLNO to generate more revenues over the next 7-years than GBT, RETA & $FOLD mgmt/BOD forecast for their products post acquisition. The 3 were acquired for enterprise values of $4.8 to $7.0B. SLNO generated 98% gross profit margins in FY25. All 3 peers forecast a lower gross profit margin on their product sales. If analysts forecast SLNO to generate more cumulative revenues over the next 7 years, does this suggest SLNO would be worth roughly the same as GBT, RETA & FOLD in a hypothetical M&A exit (assuming SLNO analyst consensus revenue estimates were credible)? This is a question for SLNO related investors. This is not investment advice. $RYTM $XBI $IBB

1 · Reply

Night_Owl_Biotech Mar. 3 at 3:48 PM

Attachment compares $SNDX 7-year (FY26 - FY32) analyst consensus revenue estimates to the 7-year revenue forecasts prepared by the mgmt/BOD of 5 SNDX peers that recently exited via M&A @ enterprise valuations of $3.7-$5.2B. SNDX 7-year analyst consensus are remarkably consistent with the average revenue forecast of the 5 peers. SNDX’s revenues also generate higher gross profit margins to date. If SNDX analyst estimates are credible AND IF SNDX’s 2 product merit peer M&A revenue multiples (2 HUGE Ifs), simple math suggests SNDX is worth considerably more in valuation should SNDX exit via M&A. SNDX market cap noted at $21.25/sh The graph compares SNDX 7-year analyst consensus v. the average revenue forecast prepared by the 5 peer comm'l-stage bios that were acquired. This is not investment advice. These data points are useless if SNDX continues as an independent going concern. Be careful, our post may also be misleading. $INCY $XBI $IBB $FOLD

2 · Reply

theoptionsplug Mar. 3 at 3:33 AM

THINGS TO WATCH, 3/3/26 👁️ $CRWD $TGT $FOLD $BMRN $VTYX

0 · Reply

BillionerOfKing Mar. 2 at 9:01 PM

$FOLD Current Stock Price: $14.36 Contracts to trade: $14.0 FOLD Mar 20 2026 Call Entry: $0.30 Exit: $0.52 ROI: 74% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

G101SPM Mar. 2 at 8:21 PM

#SHOWTIME $MIST management will present at the TD Cowen 46th Annual Health Care Conference in Boston, taking place March 2–4, 2026. A webcast of the presentation is scheduled for March 3, 2026, at 9:10 AM EST. AECOM Annual General Meeting (March 3) Scheduled to appear: $ACM Amicus Therapeutics, Inc. Extraordinary Shareholders Meeting (March 3) Scheduled to appear: $FOLD Warner Music Group Corp. Annual General Meeting (March 3) Scheduled to appear: $WMG

0 · Reply

Count_Von_Count Feb. 26 at 1:45 PM

$FOLD

0 · Reply

Estimize Feb. 25 at 3:03 PM

Wall St is expecting 0.03 EPS for $FOLD Q1 [Reporting 05/13 BMO] http://www.estimize.com/intro/fold?chart=historical&metric_name=eps&utm_co

0 · Reply

SuperGreenToday Feb. 23 at 7:04 PM

$FOLD Share Price: $14.35 Contract Selected: Dec 18, 2026 $15 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.08 Potential Upside: 67% ROI Time to Expiration: 297 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ZacksResearch Feb. 23 at 5:40 PM

$FOLD misses earnings… but revenue strength changes the tone 👀 Q4 earnings came in light, yet revenues beat estimates thanks to strong Galafold and Pombiliti sales — and the company is set to be acquired by BioMarin for $4.8 billion. That’s a powerful combo of commercial traction + strategic value. Want the full breakdown on what this means for shareholders? 👉 https://www.zacks.com/stock/news/2873684/amicus-q4-earnings-miss-higher-product-sales-drive-yy-revenues?cid=sm-stocktwits-2-2873684-teaser-34709&ADID=SYND_STOCKTWITS_TWEET_2_2873684_TEASER_34709

0 · Reply

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

Feb 3, 2026, 8:00 AM EST - 5 weeks ago

Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026

Feb 2, 2026, 5:29 AM EST - 5 weeks ago

Top 3 Health Care Stocks That May Implode In Q1

BKD MIRM

Dec 26, 2025, 3:28 PM EST - 2 months ago

Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

BMRN

Dec 22, 2025, 3:15 PM EST - 2 months ago

BioMarin: Amicus Buyout Sparks My Enthusiasm

BMRN

Dec 19, 2025, 10:55 AM EST - 3 months ago

BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

BMRN

Dec 19, 2025, 8:13 AM EST - 3 months ago

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

BMRN

Dec 19, 2025, 7:56 AM EST - 3 months ago

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

BMRN

Dec 19, 2025, 7:45 AM EST - 3 months ago

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BMRN

Nov 11, 2025, 4:56 PM EST - 4 months ago

Amicus Therapeutics: Moving Towards Consistent Profitability

Nov 10, 2025, 6:11 PM EST - 4 months ago

Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 4, 2025, 3:56 PM EST - 4 months ago

Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 4 months ago

Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates

Oct 31, 2025, 7:00 AM EDT - 4 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025

Oct 23, 2025, 7:00 AM EDT - 5 months ago

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025

Oct 22, 2025, 8:47 PM EDT - 5 months ago

Amicus Therapeutics: Turning The Corner To Profitability With 2 Developing Therapies

Sep 29, 2025, 1:15 PM EDT - 5 months ago

3 Of My Favorite Biotech Stocks Under $10

DVAX MRNA NUVB PFE

Sep 9, 2025, 6:06 PM EDT - 6 months ago

Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 9:00 AM EDT - 6 months ago

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Aug 29, 2025, 9:06 PM EDT - 7 months ago

In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful

Aug 29, 2025, 7:00 AM EDT - 7 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

Aug 25, 2025, 4:22 PM EDT - 7 months ago

Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student

Aug 21, 2025, 6:20 PM EDT - 7 months ago

In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump

Aug 18, 2025, 2:47 PM EDT - 7 months ago

The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination

Aug 1, 2025, 4:04 PM EDT - 8 months ago

Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200

Jul 31, 2025, 3:12 PM EDT - 8 months ago

Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 7:00 AM EDT - 8 months ago

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

Jul 28, 2025, 6:20 PM EDT - 8 months ago

In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data

Jul 21, 2025, 7:00 AM EDT - 8 months ago

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jul 10, 2025, 8:00 AM EDT - 8 months ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

Jun 25, 2025, 7:00 AM EDT - 9 months ago

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

Jun 20, 2025, 5:03 PM EDT - 9 months ago

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

Jun 16, 2025, 2:02 PM EDT - 9 months ago

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

Jun 13, 2025, 6:23 PM EDT - 9 months ago

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

Jun 12, 2025, 4:16 PM EDT - 9 months ago

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

Jun 12, 2025, 10:14 AM EDT - 9 months ago

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

Jun 3, 2025, 7:00 AM EDT - 10 months ago

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

May 30, 2025, 7:00 AM EDT - 10 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

May 7, 2025, 7:00 AM EDT - 11 months ago

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

May 1, 2025, 4:24 PM EDT - 11 months ago

Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 11 months ago

Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

Apr 30, 2025, 7:12 PM EDT - 11 months ago

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Apr 21, 2025, 7:00 AM EDT - 11 months ago

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

Mar 17, 2025, 10:21 AM EDT - 1 year ago

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)

Mar 6, 2025, 4:31 PM EST - 1 year ago

In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer

Mar 3, 2025, 2:04 PM EST - 1 year ago

NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act

Feb 27, 2025, 7:00 AM EST - 1 year ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

Capitulation_0 Mar. 13 at 7:55 PM

0 · Reply

Night_Owl_Biotech Mar. 11 at 2:14 AM

1 · Reply

Night_Owl_Biotech Mar. 3 at 3:48 PM

2 · Reply

theoptionsplug Mar. 3 at 3:33 AM

THINGS TO WATCH, 3/3/26 👁️ $CRWD $TGT $FOLD $BMRN $VTYX

0 · Reply

BillionerOfKing Mar. 2 at 9:01 PM

0 · Reply

G101SPM Mar. 2 at 8:21 PM

0 · Reply

Count_Von_Count Feb. 26 at 1:45 PM

$FOLD

0 · Reply

Estimize Feb. 25 at 3:03 PM

Wall St is expecting 0.03 EPS for $FOLD Q1 [Reporting 05/13 BMO] http://www.estimize.com/intro/fold?chart=historical&metric_name=eps&utm_co

0 · Reply

SuperGreenToday Feb. 23 at 7:04 PM

0 · Reply

ZacksResearch Feb. 23 at 5:40 PM

0 · Reply

ZacksResearch Feb. 23 at 4:40 PM

$FOLD's 91.7% rally in 6 months compared to the industry’s 22.8% rise — is it time to cash in? 🚀💰 Despite missing EPS estimates by 3 cents, revenue surged 24% YoY on a reported basis, beating expectations at $185.2M, thanks to strong sales from Galafold and Pombiliti + Opfolda. Now, a $4.8B acquisition by $BMRN looms for Q2 2026. Discover the full story here 👉 https://www.zacks.com/stock/news/2873684/amicus-q4-earnings-miss-higher-product-sales-drive-yy-revenues?cid=sm-stocktwits-2-2873684-body-34708&ADID=SYND_STOCKTWITS_TWEET_2_2873684_BODY_34708

0 · Reply

PhilipVilkama347 Feb. 18 at 12:44 PM

$FOLD Rare-disease biotech with commercial product; execution now matters more than science.

1 · Reply

Night_Owl_Biotech Feb. 14 at 4:02 AM

The attachment compares $SLNO analyst consensus revenue estimates to 6 peers with similar revenue dollar projections that exited via M&A. Analysts forecast SLNO to generate more revenues, and at higher gross margins, than 5 of the 6. All were acquired at meaningfully higher Year 4 & 10-year multiples. $FOLD projected 10-year revenues 1/3 less than analysts forecast for SLNO yet was acquired for 2.2X higher than SLNO's market cap. SLNO has roughly $500MM cash. If the table used SLNO's enterprise value the multiples would be 25% lower. SLNO management & BOD need to seriously consider an M&A exit if their valuation continues to be materially lower than these peers. $XBI $IBB

1 · Reply

OfficialStocktwitsUser Feb. 13 at 3:38 PM

$FOLD RSI: 59.26, MACD: 0.2315 Vol: 0.02, MA20: 14.30, MA50: 13.32 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Feb. 12 at 2:58 PM

$FOLD Share Price: $14.31 Contract Selected: Jul 17, 2026 $15 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.06 – $0.08 Potential Upside: 57% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ZacksResearch Feb. 11 at 5:48 PM

$FOLD into Q4 — buy the momentum or brace for volatility? Galafold is driving growth, with Pombiliti + Opfolda adding to the top line — and now BioMarin is set to acquire the company for $4.8 billion. That’s a major strategic twist heading into earnings. Big catalysts in play. Are you positioned right? 👀 Full breakdown before Q4 hits 👉 https://www.zacks.com/stock/news/2853843/should-investors-buy-sell-or-hold-amicus-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2853843-teaser-33143&ADID=SYND_STOCKTWITS_TWEET_2_2853843_TEASER_33143

0 · Reply

ZacksResearch Feb. 11 at 4:48 PM

$FOLD's rally continues — what’s driving the surge? 🚀 📈 Shares up 104.9% in 6 months, beating the industry’s 23.8% growth 💊 Galafold sales increased YoY and sequential Pombiliti + Opfolda sales boost revenue 🔍 Pending $4.8B acquisition by $BMRN adds upside potential See what’s next for Amicus here 👉 https://www.zacks.com/stock/news/2853843/should-investors-buy-sell-or-hold-amicus-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2853843-body-33142&ADID=SYND_STOCKTWITS_TWEET_2_2853843_BODY_33142

0 · Reply

OfficialStocktwitsUser Feb. 9 at 10:15 PM

$FOLD RSI: 47.83, MACD: 0.3028 Vol: 0.03, MA20: 14.30, MA50: 12.96 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

DailyAnalysis Feb. 8 at 5:02 PM

$FOLD 1W remains healthy, but 1D RSI is showing exhaustion. 4H STOCH is curling from the floor, and 30M CCI is breaking above -100, suggesting a tactical long entry for a short-term bounce. @DailyAnalysis

0 · Reply

DailyAnalysis Feb. 7 at 5:31 PM

$FOLD is grinding higher with 1D RSI at 56. 4H STOCH is cooling while 30M CCI stays positive. 1W setup looks solid for a breakout continuation toward the 200MA. @DailyAnalysis

0 · Reply

DailyAnalysis Feb. 6 at 9:13 PM

$FOLD 1W chart shows accumulation while 1D RSI is oversold. 4H CCI recovery suggests a trend reversal as 30M STOCH gains strength from the local lows. @DailyAnalysis

0 · Reply

ZacksResearch Jan. 28 at 5:10 PM

$FOLD vs. $RIGL — which rare disease biotech has the better upside right now? 👀 Both target rare diseases, but the setups are diverging: Amicus is tied to a pending BioMarin buyout, while Rigel is leaning on growing drug sales — two very different paths to potential upside. See which story offers the better risk/reward 👉 https://www.zacks.com/stock/news/2824519/fold-vs-rigl-which-rare-disease-biotech-stock-has-better-upside?cid=sm-stocktwits-2-2824519-teaser-30693&ADID=SYND_STOCKTWITS_TWEET_2_2824519_TEASER_30693

0 · Reply

Market Cap	4.51B
Revenue (ttm)	634.21M
Net Income (ttm)	-27.11M
EPS (ttm)	N/A
PE Ratio	479.00
Forward PE	35.05
Profit Margin	-4.27%
Debt to Equity Ratio	1.43

Volume	2,738,100
Avg Vol	7,019,646
Day's Range	N/A - N/A
Shares Out	314.00M
Stochastic %K	71%
Beta	0.43
Analysts	Sell
Price Target	$14.07